Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2011. The report details a specific share repurchase transaction executed on May 4, 2011, in accordance with shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Repurchased: 400,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,320.5 pence per share; lowest price paid was 1,302.5 pence per share.
- Treasury Shares Held: 493,224,284 shares (8.72% of total issued share capital; 9.55% of total voting rights).
- Shares in Issue: 5,164,375,994 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding share capital through the cancellation of 400,000 repurchased shares. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding share buybacks.
Key Facts for Investor Verification
- Verify the total cost of the 400,000 share repurchase based on the disclosed price range (1,302.5 to 1,320.5 pence).
- Confirm the updated total issued share capital and voting rights structure following the cancellation of these shares.
- Review the remaining authorization for share buybacks under the mandate granted at the May 2010 Annual General Meeting.
- Note that this filing does not contain operational or financial performance data for the period.